Bard’s Balloon Catheter Takes PAD Treatment To New Heights
Clinicians treating peripheral artery disease can use CR Bard’s FDA-approved Lutonix 035 drug-coated balloon with even greater confidence, in the wake of newly published research findings.
You may also be interested in...
COVID-19 led to a significant reduction in elective procedures carried out by the UK NHS, broke referral pathways, and put a virtual halt to diagnostics and screening programs. The likely next stages and the concerns of the medtech sector are top priorities for the ABHI.
The use of virtual, real-time and at-home testing to provide clinical trials data has been steadily gaining the interest of the health care industry. COVID-19 has put this opportunity into sharper focus, says CNS trials technology developer Cambridge Cognition, which is now adding a voice option to its portfolio.
This week's Device Week podcast covers recent regulatory developments in Asia in the wake of COVID-19, and how regulators are adjusting to working under the pandemic. Having published two updates from our regular Asian Medtech Associations Reg Networking discussions this week, Medtech Insight speaks to Asia Regulatory Professional Association founder Jack Wong on Asian regulatory themes and South Korea's hosting of the next International Medical Device School.